A Phase 3 interventional study of Valganciclovir and Ganciclovir in Cytomegalovirus Retinitis and HIV Infections, sponsored by Hoffmann-La Roche. Completed at 19 sites in 2 countries. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2017-05-17.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.
64 studies on the registry are indexed under Cytomegalovirus Retinitis; 2 are open to participants now.
Browse Cytomegalovirus Retinitis studies →Hoffmann-La Roche is the lead sponsor of 2,099 studies on the registry; 88 are open to participants now.
Of its 324 completed or terminated interventional studies of FDA-regulated products, 245 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
This study is completed, as verified in Jul 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valganciclovir · Ganciclovir